RG
NDRM

Redmile Group’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Redmile Group’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-76,729
Closed -$2.98M – 84
2017
Q3 		$2.98M Sell
76,729
-478,367
-86% -$17.6M 0.15% 55
2017
Q2 		$16.6M Sell
555,096
-369,208
-40% -$9.56M 1.01% 36
2017
Q1 		$24.5M Sell
924,304
-636,515
-41% -$15.8M 1.59% 23
2016
Q4 		$34.6M Buy
1,560,819
+755,573
+94% +$14.1M 2.99% 12
2016
Q3 		$14.9M Sell
805,246
-16,199
-2% -$281K 1.18% 28
2016
Q2 		$13.3M Sell
821,445
-359,442
-30% -$6.05M 1.28% 27
2016
Q1 		$16.7M Sell
1,180,887
-408,374
-26% -$5.52M 1.71% 23
2015
Q4 		$27.1M Buy
1,589,261
+126,562
+9% +$2.47M 2.03% 19
2015
Q3 		$30.2M Buy
+1,462,699
New +$30M 2.29% 19

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return

Redmile Group's NDRM Position: Q4 2017 in Review

Redmile Group sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 76,729 shares — an estimated $2.98M sold.

Redmile Group first reported a position in NDRM in Q3 2015 and held it in 9 quarters. The position peaked at $34.6M in Q4 2016. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Redmile Group reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Redmile Group sold 76,729 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $2.98M.
  • Redmile Group first reported a position in NeuroDerm Ltd. Ordinary Shares in Q3 2015 and held it in 9 quarters.
  • Redmile Group's NeuroDerm Ltd. Ordinary Shares position peaked at $34.6M in Q4 2016.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Redmile Group's 13F filing for Q4 2017, filed 14 Feb 2018.